An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Therapeutic Use
- 26 Jan 2021 Status changed from recruiting to completed.
- 25 Jan 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2023.
- 25 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2022.